Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 698 clinical trials
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives:

<ul>
  • Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B
  • Dose Expansion Part B: To assess …

    refractory multiple myeloma
    daratumumab
    pomalidomide
    proteasome inhibitor
    autologous hematopoietic stem cell transplant
    • 0 views
    • 19 Feb, 2024
    • 8 locations
    Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

    This research study involves the following investigational drugs:

    <ul>
  • Ipatasertib
  • Atezolizumab
    • ul>

    g-csf
    cfdna
    adjuvant therapy
    immunohistochemistry
    invasive breast cancer
    • 0 views
    • 19 Feb, 2024
    Cisplatin+Pembrolizumab+RT in Vulvar Cancer

    This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma.

    This research study involves the following:

    <ul>
  • Cisplatin (standard of care drug)
  • Pembrolizumab (investigational drug)
  • Radiation Therapy (standard …

    cytotoxic chemotherapy
    blood transfusion
    metastasis
    liver metastases
    squamous cell carcinoma
    • 0 views
    • 19 Feb, 2024
    Ibrutinib + Venetoclax in Untreated WM

    The names of the study drugs involved in this study are:

    <ul>
  • Venetoclax
  • ibrutinib
    • ul>

    myd88 gene mutation
    venetoclax
    plasmapheresis
    igm level
    waldenstrom's macroglobulinemia
    • 0 views
    • 19 Feb, 2024
    Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    The names of the study interventions involved in this study are:

    <ul>
  • Sacituzumab govitecan (IMMU-132)
  • Pembrolizumab (Keytruda; MK-3475)
    • ul>

    estrogen
    tubal ligation
    immunohistochemistry
    copper
    invasive breast cancer
    • 8 views
    • 19 Feb, 2024
    Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

    The name of the study intervention involved in this study is:

    <ul>
  • Implantation of a MR-guided microdevice
    • ul>

    prostatectomy
    neutrophil count
    carcinoma
    • 2 views
    • 19 Feb, 2024
    Genetic Testing for All Breast Cancer Patients (GET FACTS)

    The names of the study methods involved in this trial are/is:

    <ul>
  • Quantitative genetic counseling (discussion is guided by tables and graphs)
  • Standard genetic counseling
    • ul>

    breast cancer
    genetic testing
    genetic counseling
    cancer diagnosis
    breast carcinoma
    • 0 views
    • 19 Feb, 2024
    Dupilumab Asthma Sleep Study

    Primary Objective:

    To assess the effect of dupilumab on sleep

    Secondary Objectives:

    <ul>
  • To evaluate the effect of dupilumab on additional patient reported sleep outcomes
  • To evaluate the effect of dupilumab on objective sleep assessment
  • To evaluate the effect of dupilumab on asthma symptoms
  • To evaluate the effect …

    dupilumab
    fractional exhaled nitric oxide
    leukotriene receptor antagonist
    corticosteroids
    forced expiratory volume
    • 0 views
    • 19 Feb, 2024
    • 10 locations
    Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

    Embedded within the Master Study are individual drug substudies.

    <ul>
  • Investigational Drug Sub-study A: Brigatinib
    • ul>

    meningioma
    tubal ligation
    investigational drug
    neurofibroma
    investigational therapy
    • 0 views
    • 19 Feb, 2024
    Open Label Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

    ul>

    • 0 views
    • 19 Feb, 2024